Is ADC a rising star in solid tumor? An umbrella review of systematic reviews and meta-analyses
Abstract Background Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the potency of highly cytotoxic drugs and are known as panaceas, completely changing the treatment paradigm for solid tumors. Compared with other anti-cancer drugs, do they have better efficacy...
Furkejuvvon:
| Váldodahkkit: | , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
BMC
2025-02-01
|
| Ráidu: | BMC Cancer |
| Fáttát: | |
| Liŋkkat: | https://doi.org/10.1186/s12885-025-13726-8 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|